Morgan Stanley is out with its report today on InterMune ITMN, maintaining Equal-weight.
In its report, Morgan Stanley writes, "We attended the recent European Respiratory Society meeting which
hosted the initial symposia supporting the new German
launch of Esbriet (pirfenidone) in IPF. Our takeaways are below, with our bias being more positive than in the past on the ultimate potential of Esbriet."
At the time of posting, shares of ITMN were trading pre-market at $22.25, up 2.39% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in